ACR Meeting Abstracts

ACR Meeting Abstracts

  • Meetings
    • ACR Convergence 2024
    • ACR Convergence 2023
    • 2023 ACR/ARP PRSYM
    • ACR Convergence 2022
    • ACR Convergence 2021
    • ACR Convergence 2020
    • 2020 ACR/ARP PRSYM
    • 2019 ACR/ARP Annual Meeting
    • 2018-2009 Meetings
    • Download Abstracts
  • Keyword Index
  • Advanced Search
  • Your Favorites
    • Favorites
    • Login
    • View and print all favorites
    • Clear all your favorites
  • ACR Meetings

Abstract Number: 1396

Survivin–positivity Increases Risk For RA and Has a Strong Additive Effect On The Shared Epitope Alleles and Antibodies To Citrullinated Peptides In Patients Of The Malaysian Epidemiological Investigation Of Rheumatoid Arthritis (MyEIRA) Study Group

Chun Lai Too1, Shahnaz Murad2, Malin Erlandsson3, Heselynn Hussein4, Wahinuddin Sulaiman5, Jasbir Singh Dhaliwal1 and Maria Bokarewa3, 1Institute for Medical Research, Allergy and Immunology Research Center, Jalan Pahang, Kuala Lumpur, Malaysia, 2Institute for Medical Research, Jalan Pahang, Kuala Lumpur, Malaysia, 3Rheumatology and Inflammation Research, University of Gothenburg, Gothenburg, Sweden, 4Department of Medicine, Putrajaya Hospital, Putrajaya, Malaysia, 5Department of Medicine, Tengku Bainun Hospital, Ipoh, Perak, Malaysia

Meeting: 2013 ACR/ARHP Annual Meeting

Keywords: ACPA, Genetic Biomarkers, rheumatoid arthritis (RA) and risk assessment

  • Tweet
  • Click to email a link to a friend (Opens in new window) Email
  • Click to print (Opens in new window) Print
Session Information

Title: Rheumatoid Arthritis - Human Etiology and Pathogenesis

Session Type: Abstract Submissions (ACR)

Background/Purpose:

The human leukocyte antigen (HLA)-DRB1 with alleles that contain common amino acid motif QKRAA termed shared epitope (SE) confer the major locus of genetic susceptibility to rheumatoid arthritis (RA). Molecular basis of  tolerance loss marked by autoantibody production remains to be resolved.  The aim of this study was to analyse an association between survivin, oncoprotein recently reported to be associated with early bone damage and poor therapy response, HLA-DRB1 SE alleles and antibodies to citrullinated peptides (ACPA) in Malaysian patients.

Methods: :   1233 RA patients and 1566  age, sex and ethnically matched healthy controls of the Malaysian Epidemiological Investigation of rheumatoid arthritis (MyEIRA) study group were included in the study. The levels of survivin, ACPA and rheumatoid factor were measured by specific and standardized ELISAs. HLA-DRB1 genotyping was performed by the PCR-SSO method. Among the HLA-DRB1 alleles, DRB1*01, DRB1*0401, DRB1*0404, DRB1*0405, DRB1*0408, DRB1*0410, and DRB1*10 were defined as SE alleles. The odds ratio (OR[95%CI]) and relative risk (RR) of developing ACPA-positive and ACPA-negative RA was calculated for survivin and the presence of any SE allele. Potential interaction between survivin and HLA-DRB1 SE alleles was also calculated. 

Results: The prevalence of survivin-positivity among RA patients was 50.7%, compared to 5.4% in healthy controls (p=2.66E-164) with a significantly higher prevalence in the  Indian ethnic population compared to the Malay and Chinese (p<0.0001). Survivin-positivity was associated with an increased risk of developing ACPA-positive RA (OR 33.5[25.8-43.6]) and ACPA-negative RA (OR 5.3[3.9-7.2]), both p<0.0001. The survivin-positivity was associated with SE-alleles in 23.6% of RA patients and the majority of patients combining survivin and SE (91%) were also ACPA–positive.  The combination of survivin-positivity and SE increased the risk of ACPA-positive RA 19 folds. 

Conclusion: The survivin-positivity increases risk of the development of ACPA-positive and ACPA-negative RA. Combination of survivin-positivity, SE and APCA has a strong additive effect for the risk of RA in the population from Malaysia.


Disclosure:

C. L. Too,
None;

S. Murad,
None;

M. Erlandsson,
None;

H. Hussein,
None;

W. Sulaiman,
None;

J. S. Dhaliwal,
None;

M. Bokarewa,
None.

  • Tweet
  • Click to email a link to a friend (Opens in new window) Email
  • Click to print (Opens in new window) Print

« Back to 2013 ACR/ARHP Annual Meeting

ACR Meeting Abstracts - https://acrabstracts.org/abstract/survivin-positivity-increases-risk-for-ra-and-has-a-strong-additive-effect-on-the-shared-epitope-alleles-and-antibodies-to-citrullinated-peptides-in-patients-of-the-malaysian-epidemiologi/

Advanced Search

Your Favorites

You can save and print a list of your favorite abstracts during your browser session by clicking the “Favorite” button at the bottom of any abstract. View your favorites »

All abstracts accepted to ACR Convergence are under media embargo once the ACR has notified presenters of their abstract’s acceptance. They may be presented at other meetings or published as manuscripts after this time but should not be discussed in non-scholarly venues or outlets. The following embargo policies are strictly enforced by the ACR.

Accepted abstracts are made available to the public online in advance of the meeting and are published in a special online supplement of our scientific journal, Arthritis & Rheumatology. Information contained in those abstracts may not be released until the abstracts appear online. In an exception to the media embargo, academic institutions, private organizations, and companies with products whose value may be influenced by information contained in an abstract may issue a press release to coincide with the availability of an ACR abstract on the ACR website. However, the ACR continues to require that information that goes beyond that contained in the abstract (e.g., discussion of the abstract done as part of editorial news coverage) is under media embargo until 10:00 AM ET on November 14, 2024. Journalists with access to embargoed information cannot release articles or editorial news coverage before this time. Editorial news coverage is considered original articles/videos developed by employed journalists to report facts, commentary, and subject matter expert quotes in a narrative form using a variety of sources (e.g., research, announcements, press releases, events, etc.).

Violation of this policy may result in the abstract being withdrawn from the meeting and other measures deemed appropriate. Authors are responsible for notifying colleagues, institutions, communications firms, and all other stakeholders related to the development or promotion of the abstract about this policy. If you have questions about the ACR abstract embargo policy, please contact ACR abstracts staff at [email protected].

Wiley

  • Online Journal
  • Privacy Policy
  • Permissions Policies
  • Cookie Preferences

© Copyright 2025 American College of Rheumatology